Pharma giants announce diabetes drug partnership

04/29/2013 | PharmaLive.com

Merck and Pfizer announced plans to combine Merck's DPP-4 inhibitor Januvia with Pfizer's SGLT-2 inhibitor ertugliflozin to treat type 2 diabetes. Merck paid Pfizer $60 million and will split costs and revenue 60-40 with Pfizer. "This is like the Yankees and Red Sox combining their scouting departments," former Pfizer research chief John LaMattina wrote on Twitter, but Diabetic Investor publisher David Kliff said the resulting drug will be just "another tool in the toolbox."

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC